{
  "ticker": "NSB",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02971762",
  "id": "02971762",
  "pages": 10,
  "price_sensitive": true,
  "date": "20250723",
  "time": "0918",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250723/pdf/06m1r6th6922jq.pdf",
  "summary": "### **Material Information Summary (ASX: NSB - Quarterly Report - 30 June 2025)**  \n\n#### **Key Highlights:**  \n- **Acquisition:** Completed 100% acquisition of Isopogen WA Ltd, securing **StemSmart\u2122** patented stem cell technology.  \n- **Clinical Progress:**  \n  - **Phase 2 Refractory Crohn\u2019s trial:** 18 patients showed clinical improvement/remission.  \n  - **Special Access Program (SAS) launched** for fistulising Crohn\u2019s disease, targeting unmet need.  \n  - Positive historical results in steroid-refractory GVHD (adults/children).  \n- **FDA Precedent:** FDA approval of rival MSC therapy (Mesoblast) noted as validation for sector.  \n- **Capital Raising:** **$3.5M (before costs)** raised via institutional/sophisticated investor Placement.  \n\n#### **Financials:**  \n- **Cash balance (30 June 2025):** **A$7.3M** (~19 quarters of runway).  \n- **R&D spend (quarter):** A$50K; **Corporate costs:** A$261K.  \n- **Post-quarter:** Received A$320K R&D tax rebate (1 July 2025).  \n\n#### **Market Opportunities:**  \nAddressable markets cited:  \n- **Crohn\u2019s disease (US$13.8B by 2026)**  \n- **GVHD (US$5.31B by 2032)**  \n\n*Omitted: Board changes, operational details without material impact.*  \n\n**Format:** Strictly concise, trading-relevant data only. No speculation or narrative.",
  "usage": {
    "prompt_tokens": 5159,
    "completion_tokens": 346,
    "total_tokens": 5505,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-22T23:30:51.152813"
}